Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

C. Pellegrini, A. Broccoli, A. Pulsoni, L. Rigacci, C. Patti, G. Gini, D. Mannina, M. Tani, C. Rusconi, A. Romano, A. Vanazzi, B. Botto, A. Santoro, S. Hoaus, G.M. Rigolin, P. Musto, P. Mazza, S. Molica, P. Corradini, A. FamaF. Gaudio, M. Merli, F. Ronconi, G. Gritti, D. Vallisa, P. Tosi, A.M. Liberati, A. Pinto, V. Pavone, F. Gherlinzoni, M.P. Bianchi, S. Volpetti, L. Trentin, M.C. Goldaniga, M. Bonfichi, A.D. Renzo, C. Schiavotto, M. Spina, A.M. Carella, V. Stefoni, L. Argnani, P.L. Zinzani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. © Pellegrini et al.
Original languageEnglish
Pages (from-to)91703-91710
Number of pages8
JournalOncotarget
Volume8
Issue number53
Publication statusPublished - 2017

Fingerprint

Life Change Events
Hodgkin Disease
Observational Studies
Transplants
Disease-Free Survival
cAC10-vcMMAE
Retrospective Studies
Clinical Trials
Therapeutics

Keywords

  • Brentuximab vedotin
  • Hodgkin's lymphoma
  • Long-term response
  • Real life
  • Stem cell transplantation
  • brentuximab vedotin
  • CD30 antigen
  • acute myeloid leukemia
  • adult
  • adult respiratory distress syndrome
  • aged
  • allogeneic stem cell transplantation
  • Article
  • cancer recurrence
  • clinical practice
  • disease free survival
  • disease severity
  • drug dose reduction
  • drug efficacy
  • drug response
  • drug safety
  • drug tolerability
  • female
  • follow up
  • histopathology
  • Hodgkin disease
  • human
  • incidence
  • Italy
  • major clinical study
  • male
  • multiple cycle treatment
  • neutropenia
  • observational study
  • overall survival
  • pancreatitis
  • pancytopenia
  • peripheral neuropathy
  • personal experience
  • progression free survival
  • respiratory failure
  • retrospective study
  • sensory neuropathy
  • thrombocytopenia
  • treatment duration

Cite this

Pellegrini, C., Broccoli, A., Pulsoni, A., Rigacci, L., Patti, C., Gini, G., ... Zinzani, P. L. (2017). Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. Oncotarget, 8(53), 91703-91710.

Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. / Pellegrini, C.; Broccoli, A.; Pulsoni, A.; Rigacci, L.; Patti, C.; Gini, G.; Mannina, D.; Tani, M.; Rusconi, C.; Romano, A.; Vanazzi, A.; Botto, B.; Santoro, A.; Hoaus, S.; Rigolin, G.M.; Musto, P.; Mazza, P.; Molica, S.; Corradini, P.; Fama, A.; Gaudio, F.; Merli, M.; Ronconi, F.; Gritti, G.; Vallisa, D.; Tosi, P.; Liberati, A.M.; Pinto, A.; Pavone, V.; Gherlinzoni, F.; Bianchi, M.P.; Volpetti, S.; Trentin, L.; Goldaniga, M.C.; Bonfichi, M.; Renzo, A.D.; Schiavotto, C.; Spina, M.; Carella, A.M.; Stefoni, V.; Argnani, L.; Zinzani, P.L.

In: Oncotarget, Vol. 8, No. 53, 2017, p. 91703-91710.

Research output: Contribution to journalArticle

Pellegrini, C, Broccoli, A, Pulsoni, A, Rigacci, L, Patti, C, Gini, G, Mannina, D, Tani, M, Rusconi, C, Romano, A, Vanazzi, A, Botto, B, Santoro, A, Hoaus, S, Rigolin, GM, Musto, P, Mazza, P, Molica, S, Corradini, P, Fama, A, Gaudio, F, Merli, M, Ronconi, F, Gritti, G, Vallisa, D, Tosi, P, Liberati, AM, Pinto, A, Pavone, V, Gherlinzoni, F, Bianchi, MP, Volpetti, S, Trentin, L, Goldaniga, MC, Bonfichi, M, Renzo, AD, Schiavotto, C, Spina, M, Carella, AM, Stefoni, V, Argnani, L & Zinzani, PL 2017, 'Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma', Oncotarget, vol. 8, no. 53, pp. 91703-91710.
Pellegrini, C. ; Broccoli, A. ; Pulsoni, A. ; Rigacci, L. ; Patti, C. ; Gini, G. ; Mannina, D. ; Tani, M. ; Rusconi, C. ; Romano, A. ; Vanazzi, A. ; Botto, B. ; Santoro, A. ; Hoaus, S. ; Rigolin, G.M. ; Musto, P. ; Mazza, P. ; Molica, S. ; Corradini, P. ; Fama, A. ; Gaudio, F. ; Merli, M. ; Ronconi, F. ; Gritti, G. ; Vallisa, D. ; Tosi, P. ; Liberati, A.M. ; Pinto, A. ; Pavone, V. ; Gherlinzoni, F. ; Bianchi, M.P. ; Volpetti, S. ; Trentin, L. ; Goldaniga, M.C. ; Bonfichi, M. ; Renzo, A.D. ; Schiavotto, C. ; Spina, M. ; Carella, A.M. ; Stefoni, V. ; Argnani, L. ; Zinzani, P.L. / Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 53. pp. 91703-91710.
@article{00d6a53bbfdb44c7bb7605dafc33e148,
title = "Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma",
abstract = "A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8{\%}): 74 (31.6{\%}) patients obtained a complete response (CR) and 66 (28.2{\%}) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3{\%} (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50{\%}) CR and 5 (17.8{\%}) PR. Disease free survival was 26.3{\%} at 3 years and progression free survival 31.9{\%} at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. {\circledC} Pellegrini et al.",
keywords = "Brentuximab vedotin, Hodgkin's lymphoma, Long-term response, Real life, Stem cell transplantation, brentuximab vedotin, CD30 antigen, acute myeloid leukemia, adult, adult respiratory distress syndrome, aged, allogeneic stem cell transplantation, Article, cancer recurrence, clinical practice, disease free survival, disease severity, drug dose reduction, drug efficacy, drug response, drug safety, drug tolerability, female, follow up, histopathology, Hodgkin disease, human, incidence, Italy, major clinical study, male, multiple cycle treatment, neutropenia, observational study, overall survival, pancreatitis, pancytopenia, peripheral neuropathy, personal experience, progression free survival, respiratory failure, retrospective study, sensory neuropathy, thrombocytopenia, treatment duration",
author = "C. Pellegrini and A. Broccoli and A. Pulsoni and L. Rigacci and C. Patti and G. Gini and D. Mannina and M. Tani and C. Rusconi and A. Romano and A. Vanazzi and B. Botto and A. Santoro and S. Hoaus and G.M. Rigolin and P. Musto and P. Mazza and S. Molica and P. Corradini and A. Fama and F. Gaudio and M. Merli and F. Ronconi and G. Gritti and D. Vallisa and P. Tosi and A.M. Liberati and A. Pinto and V. Pavone and F. Gherlinzoni and M.P. Bianchi and S. Volpetti and L. Trentin and M.C. Goldaniga and M. Bonfichi and A.D. Renzo and C. Schiavotto and M. Spina and A.M. Carella and V. Stefoni and L. Argnani and P.L. Zinzani",
note = "Export Date: 21 February 2018 Correspondence Address: Zinzani, P.L.; Institute of Hematology 'L. e A. Ser{\`a}gnoli', University of BolognaItaly; email: pierluigi.zinzani@unibo.it",
year = "2017",
language = "English",
volume = "8",
pages = "91703--91710",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "53",

}

TY - JOUR

T1 - Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

AU - Pellegrini, C.

AU - Broccoli, A.

AU - Pulsoni, A.

AU - Rigacci, L.

AU - Patti, C.

AU - Gini, G.

AU - Mannina, D.

AU - Tani, M.

AU - Rusconi, C.

AU - Romano, A.

AU - Vanazzi, A.

AU - Botto, B.

AU - Santoro, A.

AU - Hoaus, S.

AU - Rigolin, G.M.

AU - Musto, P.

AU - Mazza, P.

AU - Molica, S.

AU - Corradini, P.

AU - Fama, A.

AU - Gaudio, F.

AU - Merli, M.

AU - Ronconi, F.

AU - Gritti, G.

AU - Vallisa, D.

AU - Tosi, P.

AU - Liberati, A.M.

AU - Pinto, A.

AU - Pavone, V.

AU - Gherlinzoni, F.

AU - Bianchi, M.P.

AU - Volpetti, S.

AU - Trentin, L.

AU - Goldaniga, M.C.

AU - Bonfichi, M.

AU - Renzo, A.D.

AU - Schiavotto, C.

AU - Spina, M.

AU - Carella, A.M.

AU - Stefoni, V.

AU - Argnani, L.

AU - Zinzani, P.L.

N1 - Export Date: 21 February 2018 Correspondence Address: Zinzani, P.L.; Institute of Hematology 'L. e A. Seràgnoli', University of BolognaItaly; email: pierluigi.zinzani@unibo.it

PY - 2017

Y1 - 2017

N2 - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. © Pellegrini et al.

AB - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. © Pellegrini et al.

KW - Brentuximab vedotin

KW - Hodgkin's lymphoma

KW - Long-term response

KW - Real life

KW - Stem cell transplantation

KW - brentuximab vedotin

KW - CD30 antigen

KW - acute myeloid leukemia

KW - adult

KW - adult respiratory distress syndrome

KW - aged

KW - allogeneic stem cell transplantation

KW - Article

KW - cancer recurrence

KW - clinical practice

KW - disease free survival

KW - disease severity

KW - drug dose reduction

KW - drug efficacy

KW - drug response

KW - drug safety

KW - drug tolerability

KW - female

KW - follow up

KW - histopathology

KW - Hodgkin disease

KW - human

KW - incidence

KW - Italy

KW - major clinical study

KW - male

KW - multiple cycle treatment

KW - neutropenia

KW - observational study

KW - overall survival

KW - pancreatitis

KW - pancytopenia

KW - peripheral neuropathy

KW - personal experience

KW - progression free survival

KW - respiratory failure

KW - retrospective study

KW - sensory neuropathy

KW - thrombocytopenia

KW - treatment duration

M3 - Article

VL - 8

SP - 91703

EP - 91710

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 53

ER -